Dysregulation of cell surface proteolysis has been strongly implicated in tumorigenicity and metastasis. In this study, we delineated the role of hepatocyte growth factor activator inhibitor-2 (HAI-2) in prostate cancer (PCa) cell migration, invasion, tumorigenicity and metastasis using a human PCa progression model (103E, N1, and N2 cells) and xenograft models. N1 and N2 cells were established through serial intraprostatic propagation of 103E human PCa cells and isolation of the metastatic cells from nearby lymph nodes. The invasion capability of these cells was revealed to gradually increase throughout the serial isolations (103EoN1oN2). In this series of cells, the expression of HAI-2 but not HAI-1 was significantly decreased throughout the progression and occurred in parallel with increased activation of matriptase. The expression level and activity of matriptase increased whereas the HAI-2 protein level decreased over the course of orthotopic tumor growth in mice, which was consistent with the immunohistochemical profiles of matriptase and HAI-2 in archival PCa specimens. Knockdown of matriptase reduced the PCa cell invasion induced by HAI-2 knockdown. HAI-2 overexpression or matriptase silencing in N2 cells downregulated matriptase activity and significantly decreased tumorigenicity and metastatic capability in orthotopically xenografted mice. These results suggest that during the progression of human PCa, matriptase activity is primarily controlled by HAI-2 expression. The imbalance between HAI-2 and matriptase expression led to matriptase activation, thereby increasing cell migration, invasion, tumorigenicity and metastasis.
INTRODUCTION
Cell invasion and metastasis are the life-threatening aspects of malignancies including prostate cancer (PCa). 1, 2 The acquisition of invasive capacity involves many alterations in the proteins that regulate cell-cell and cell-matrix interactions, including the extracellular matrix-modulating proteases. 3 Among these proteins, membrane-anchored proteases have received recent attention, owing to their aberrant proteolytic actions in extracellular matrix degradation and/or the activation of membraneassociated substrates, ligands or receptors 4 that contribute to tumorigenesis and metastasis. 5, 6 Matriptase is a membrane-anchored serine protease, first identified in breast cancer cells. 7, 8 This protease is mainly expressed in the epithelial components of tissues, 9 and often coexpressed with a cognate inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1). [10] [11] [12] In the clinical context, the ratio of matriptase to HAI-1 is known to be increased in many cancers such as breast 13 and prostate; 14 an aberration that is often associated with poor prognosis. Moreover, matriptase has recently been shown to be involved in ErbB-2-promoted PCa cell invasion. 15 Aberrant matriptase activity has been strongly implicated in carcinogenesis 16 and cancer progression 17, 18 and several of the matriptase-activated substrates identified, such as hepatocyte growth factor (HGF), protease-activated receptor-2 (PAR2), matrix metalloproteinase-3 (MMP3) and urokinase plasminogen activator (uPA), are involved in promoting cell motility and invasion. [19] [20] [21] Moreover, matriptase can also directly degrade extracellular matrix including laminin and fibronectin. 22 Thus, dysregulation of matriptase may lead to enhanced malignant progression of tumors through enhanced invasive and metastatic potential.
HAI-2 was isolated from the conditioned medium of a human stomach carcinoma cell line, identified as a serine protease inhibitor, and named after its homolog HAI-1. 23 The protein was also independently identified as placental bikunin, a transmembrane glycoprotein with two Kunitz domains. 23, 24 The HAI-2 transcript is detectable in a variety of human tissues, with relatively high levels of expression in the kidney, placenta and prostate. 23, 24 In addition to epithelial cells, HAI-2 expression is also found in nonepithelial cells in the brain and lymph nodes. 25 Thus, HAI-2 has been proposed to have a physiological role in targeting a broad spectrum of serine proteases.
Altered levels of HAI-2 have been implicated in several human diseases. Syndromic congenital sodium diarrhea has been shown to be caused by loss of HAI-2 function. 26 Upregulation of HAI-2 expression in cholangiopathies affects liver fibrosis and differentiation. 27 In mice, HAI-2 is essential for placental development, neural tube closure and embryonic survival. 28 The levels of HAI-2 gene expression are reported to be downregulated in several cancers including breast cancer 29 and PCa, 30 although in pancreatic cancer, HAI-2 expression has been shown to be upregulated. 31 The loss of HAI-2 expression in cancer appears to be mainly because of epigenetic silencing by DNA hypermethylation at CpG islands in the promoter region. [32] [33] [34] HAI-2 expression has been proposed as a marker of favorable prognosis by virtue of its suppressive activity on cell growth, tumorigenesis and cancer cell invasion. 32, 33, 35 Through biochemical and genetic analysis, HAI-2 has been shown to be a potential inhibitor of hepsin and matriptase. 25, 36 However, the role of HAI-2 in the PCa progression remains poorly understood. In this study, we established a human PCa metastatic progression model by repeated isolation of PCa cells that spontaneously metastasized from the prostate to regional lymph nodes in mice. Analysis of data generated with this model showed that HAI-2 was downregulated and matriptase was upregulated in metastatic PCa cells. This observation was further corroborated by results from the immunohistochemical analyses of a longitudinal series of orthotopic xenografted prostate tumors and human archival specimens. Increasing the level of matriptase in PCa cells resulted in enhanced cell migration, invasion, tumorigenicity and metastasis, all of which were specifically counteracted by a concomitant increase in the level of HAI-2. These data support the notion that downregulation of HAI-2 in PCa can promote enhanced proteolytic activity and accelerate tumor progression.
RESULTS

Propagation of a human prostate cancer cell line in the mouse prostate results in spontaneous metastasis
To try to mimic the progression of human PCa, we established a human PCa metastatic progression model by implanting human PCa cells into the mouse prostate, allowing them to grow, and isolating the metastatic cancer cells that escaped the confines of the prostate to reach the nearby lymph nodes (Figure 1a) . In order to track the metastasis of PCa cells in the mouse body, we first transfected CWR22Rv1 cells with a luciferase reporter plasmid driven by the prostate-specific antigen promoter, and selected a stable clone with strong prostate-specific antigen promoter activity that we named 103E cells. 37 Orthotopic xenografts were then initiated by implanting 103E cells into the anterior prostate glands of nude mice. After 9-12 weeks of tumor growth, metastatic cells that had colonized the lumbar lymph nodes nearby the prostate were isolated and named N1 cells (Figure 1a , middle panel). N1 cells were again engrafted into anterior prostates of mice and we observed that the metastasis of cells to the lymph node occurred in a shorter interval of 4-6 weeks after the implantation. Once again the metastatic cells were retrieved from the lumbar lymph nodes and called N2 cells (Figure 1a, right panel) . Thus, 103E cells are parental cells with low metastatic capability and N2 cells derived from this animal model may have acquired a more aggressive phenotype.
The invasion and metastatic potential of PCa cells is correlated with increased matriptase and decreased HAI-2 expression in vivo To characterize the relative cell invasion potentials of 103E, N1 and N2 cells, Matrigel-coated Boyden chambers were used to examine the ability of the cells to penetrate through a layer of Matrigel-a standard assay of invasiveness. As expected, 103E cells were found to be less invasive than N1 and N2 cells, which exhibited progressively increased invasion activity up to approximately fourfold that of the parental cells (Figure 1b) . Thus, the gradual change in cancer cell invasion from 103E to N1 and then N2 cells may reflect the different metastatic potentials during PCa progression.
Decreased levels of matriptase inhibitors HAI-1 and HAI-2, and/or increased matriptase, have been implicated in PCa progression. 14, 30 Therefore, we analyzed the expression levels of HAI-1, HAI-2 and matriptase by quantitative polymerase chain reaction (qPCR) in the cells of this cancer progression model. Relative to 103E cells, the level of HAI-2 expression but not that of HAI-1 was downregulated by B50% in N2 cells following progression, whereas the matriptase expression level was significantly increased in N1 and N2 cells (Figure 1c ). These observations suggest that during progression, human PCa may alter pericellular proteolysis by upregulating matriptase, downregulating HAI-2 expression or both. The shift in the balance of matriptase and HAI-2 levels correlated with the increase in cellular invasion and metastatic potentials.
HAI-2 expression and matriptase activity are altered during tumorigenicity and metastasis of orthotopic PCa xenograft in mice Next, to analyze the expression of HAI-1, HAI-2 and matriptase in vivo during the prostate tumor growth, orthotopic xenografts of 103E tumors in nude mice were resected 4, 9 and 15 weeks after the implantation of the cells, and the tumor specimens were stained with antibodies specific for HAI-1, HAI-2, total matriptase and the activated form of matriptase. During the harvest of the tumors at the 15-week time point, several metastatic nodules were observed in the lymph nodes and lungs of the animals, and hence these tissues were also collected for further analysis. Immunohistochemistry (IHC) revealed that during the tumor growth, HAI-2 protein levels, but not those of HAI-1, fell progressively, whereas in contrast, the matriptase protein level increased (Figure 1d , left three columns). This altered expression was particularly marked between the 9-and 15-week time points during which a dramatic decrease in HAI-2 and increase in matriptase occurred. This change agreed with the gene expression levels examined by qPCR (Figure 1e ), and correlated with the time at which the N1 cells were isolated from the nearby lymph nodes (Figure 1a , middle panel). IHC showed that the level of HAI-2 in the metastatic nodules within the lymph nodes and lungs was similar to that in the 15-week orthotopic tumors (Figure 1d , lower panel). Although HAI-1 expression in the lymph node and pulmonary metastasis was marginally to moderately lower than in the other tumor specimens, alterations in HAI-1 level were not obvious during the growth of the primary tumors (Figures 1d and e, left panels) . In addition, the IHC images may reveal that HAI-1 expression seemed to switch from predominantly membranous expression (up to 15 weeks) to a cytoplasmic (intracellular) pattern in the lymph node and lung metastasis. In contrast to the decrease in HAI-2 levels, matriptase expression levels and activation increased along with the tumorigenesis (Figure 1d , middle to right columns). These data suggest that loss of HAI-2 or gain of function of matriptase in PCa cells may be involved in the acquisition of an invasive phenotype, and the combination of decreased HAI-2 and increased matriptase levels may promote PCa metastasis to distant organs.
The relative levels of matriptase and HAI-2 expression are inversely correlated in clinical prostate cancer In order to explore whether these intriguing findings might be replicated in clinical specimens, we next investigated the HAI-2 and matriptase protein levels in archival specimens of human PCa by IHC. The antibodies used for the staining have all been well characterized previously 38, 39 and also as shown in Supplementary  Figure 1 . The results (Figure 2a ) from two representative patients showed that HAI-2 expression was lower in the patient with Gleason score 8-10 than that in the patient with Gleason score 4-7, whereas matriptase expression was higher in the patient with the higher Gleason score. The staining was further evaluated visually using a three-point scale (0, no staining; þ 1, weak staining; þ 2, moderate staining; þ 3, strong staining) to score a tumor 410% of cells with elevated protein levels of matriptase or HAI-2 in prostate cancer tumorigenicity and metastasis C-H Tsai et al Figure 1 . (a) Establishment of a human PCa progression model by orthotopic xenograft in mice. The 103E cells derived from CWR22Rv1 cells by stable transfection with a luciferase reporter gene driven by the prostate-specific antigen (PSA) promoter were implanted into the anterior prostate of mice. At 9-12 weeks after implantation, the cells with luciferase activity were isolated from nearby lymph nodes and named N1 cells. The N1 cells were then also orthotopically injected into the anterior prostate of mice. N1 cells metastasized to the proximate lymph nodes in a shorter period than before (4-6 weeks) and were isolated and named N2 cells. (b) Analysis of the invasive potential of 103E, N1 and N2 cells by transwell assays. Each subline was seeded at 3 Â 10 5 cells per well in the upper well of a Matrigel-coated Boyden chamber in serum-free media. The lower chamber of each transwell was filled with RPMI-1640 media containing 8% fetal bovine serum (FBS) as chemoattractant and the chambers were cultivated for 16 h. Invasive cells were stained with crystal violet, photographed with a microscope and quantified using ImageJ analysis software (Bethesda, MD, USA). Data represent mean±s.d. of three independent experiments. (c) Analysis of matriptase (MTX), HAI-1 and HAI-2 mRNA levels by qPCR in 103E, N1 and N2 cells. Total RNA was prepared from the indicated cells with Trizol reagent, reversely transcribed and subjected to qPCR analysis with a set of MTX, HAI-1 and HAI-2 primers and using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control. After qPCR, the gene expression levels were statistically calculated with ratios to 103E cells. (d) IHC analysis of HAI-1, HAI-2, matriptase and activated matriptase in orthotopic xenograft tumors, and metastatic lesions in the lymph nodes and lung. The 103E cells were orthotopically implanted into the anterior prostate of mice. After implantation, the local tumors were harvested from mice euthanized 4, 9 and 15 weeks after injection. Metastatic lesions were excised from the 15 mice from the lymph nodes and lung. Tumor tissues were embedded with paraffin, used for tissue array preparation and immunohistochemically stained with specific antibodies (Abs) as marked. The images were visualized with 3,3'-diaminobenzidine (DAB) and photographed under a light microscope. Scale bar ¼ 25 mM. (e) The tumor tissues harvested from the mice at 4, 9 and 15 weeks after injection were used for RNA extraction, reverse transcription and qPCR analysis for the expression levels of HAI-1, HAI-2 and matriptase as described previously. *Po0.05; **Po0.01. qPCR, quantitative polymerase chain reaction. Figure 2b , B74% (20/27 cases) of HAI-2 immunostaining in Gleason score 4-7 PCa specimens had scores of X þ 2, whereas B57% (12/21 cases) of the HAI-2 staining levels in Gleason score 8-10 cancer tissues were o2. Matriptase immunostaining in Gleason score 4-7 cancer tissues had predominately lower intensity (22/27 cases (B81.5%) having scores of 0 or þ 1), whereas 13/21 cases (B61.9%) in the Gleason score 8-10 group had matriptase immunostaining scores of þ 2 or þ 3. Compared with Gleason score 4-7 tumor tissues, HAI-2 protein expression was significantly lower in advanced PCa (Gleason scores 8-10; Fisher's exact test P ¼ 0.039), whereas the matriptase protein level was found to be significantly increased (Fisher's exact test P ¼ 0.0029). Among advanced PCa patients, 5 patients (5/21 cases) simultaneously exhibited a decrease in HAI-2 expression and an increase in matriptase expression. The gene expression levels of HAI-2 in patients with Gleason scores 6-7 and 8-9 were significantly reduced as compared with normal individuals (Supplementary Figure 1C) . The observation that low levels of HAI-2 or higher levels of matriptase staining were associated with tumor progression as assessed by Gleason score was consistent with the pattern of acquired changes in the levels of these proteins observed in the orthotopic xenograft model (Figure 1d ), suggesting the potential involvement of HAI-2 and matriptase in the development of metastatic PCa.
HAI-2. As shown in
Matriptase activity in PCa cells is enhanced during lymph node metastasis The activation of matriptase is tightly regulated in normal tissues, and increased activation of this enzyme has been associated with malignant progression. 17, [40] [41] [42] Therefore, to analyze matriptase activation levels in 103E, N1 and N2 cells, we next used antibodies for total matriptase, activated matriptase and HAI-1.
17, 43 The results (Figure 3a) showed that the level of activated matriptase, detectable as a 120-kDa complex with HAI-1, was increased in N1 cells as compared with 103E cells and was increased again in comparing N2 with N1 cells-concomitant with their more aggressive properties. Moreover, M69 staining further revealed that the level of activated matriptase increased from 103E to N1 and again to N2 cells (Figure 3a , bottom panel), again correlating with the invasive potential of the cells (Figure 1b) , the upregulation of matriptase and the downregulation of HAI-2 ( Figure 1c) . These results suggest that the imbalance between matriptase and HAI-2 in favor of proteolysis may also contribute to matriptase activation during PCa progression.
Matriptase enhances prostate cancer cell invasion To further examine the role of matriptase in PCa cell invasion, we transfected the poorly invasive 103E cells with a matriptase expression vector and analyzed the effect of enhanced matriptase levels on cell invasion using the cell invasion assay. Overexpression of matriptase in 103E cells significantly increased the level of active enzyme (Figure 3b ) and the cell invasion by approximately fivefold (Figure 3c ). It appears, therefore, that PCa cells may enhance matriptase activation by increasing matriptase expression to promote their malignant behavior.
Expression of HAI-2 in 103E, N1 and N2 cells To further clarify the role of HAI-2 in human PCa progression, we examined HAI-2 protein expression levels in 103E, N1 and N2 cells by immunoblotting. The HAI-2 antibody detected a stack of multiple bands ranging from 34 to 50 kDa that were of somewhat reduced intensity in N1 cells as compared with 103E cells, and were much less intense in N2 cells (Figure 4a, upper panel) . HAI-2 is believed to be a highly glycosylated protein, and hence we suspected that the multiple bands observed with the HAI-2 antibody were because of the presence of multiple glycosylated Intensity scoring (0, no staining; þ 1, weak staining; þ 2, moderate staining; and þ 3, strong staining) was conducted, and Fisher's exact test was used to evaluate the intensity differences (intensity score X þ 2 vs o þ 2) of IHC signals of HAI-2 or matriptase between tissues with higher and lower Gleason scores. The P-values of Fisher's exact test for HAI-2 and matriptase staining between the two groups with higher and lower Gleason scores were 0.039 and 0.003, respectively. A two-sided P-value of o0.05 was considered statistically significant. *Po0.05; **Po0.005.
forms of the protein. To confirm the specificity of the HAI-2 antibody, and to test this hypothesis, we constructed a HAI-2 mammalian expression plasmid that included a Myc epitope tag and used this construct to transfect N2 cells, in which HAI-2 levels are apparently quite low. N2 cells transfected with the empty vector or expressing the tagged HAI-2 construct were cultured in the presence or absence of the N-glycosylation inhibitor tunicamycin. The results (Figure 4a , lower panel) from western blot analysis with anti-Myc and anti-HAI-2 antibodies showed that an array of bands similar to that seen with the HAI-2 antibody was detected in the lysates from the cells transfected with the tagged HAI-2 construct. Treatment with tunicamycin resulted in the detection of a single strong band of B34 kDa, consistent with the unglycosylated size of HAI-2. These results suggest that HAI-2 has multiple N-glycosylation forms or biosynthetic intermediates, resulting in the molecular masses of HAI-2 in whole cell lysate reflecting the different extents of glycosylation. Together, the data indicated that the level of HAI-2 protein was inversely correlated with PCa cell invasion and metastatic capability.
HAI-2 plays inhibitory roles in prostate cancer cell invasion and migration To further investigate whether HAI-2 expression might have any causal relationship with PCa cell invasion and migration, we overexpressed HAI-2 in N2 cells, and examined the effect of this intervention on cell migration and invasion. The ectopic expression of HAI-2 in the stable N2/HAI-2 cells was verified by western blot analyses (Figure 4b) . As a result of HAI-2 overexpression in N2 cells, matriptase activation was drastically reduced, resulting in the loss of the 120 kDa matriptase/HAI-1 complex (Figure 4b , middle to lower panels). Using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, ectopic expression of HAI-2 had no significant effect on the growth of N2 cells within 2 days (Supplementary Figure 2B) . We then performed cell migration and invasion assays within 16 h and found that enhanced HAI-2 expression caused a marked decrease (B40%) in both the invasion capability and chemoattractive migration as compared with control cells (Figure 4c) .
To further confirm the inhibitory role of HAI-2 in matriptase activation, cell migration and invasion in PCa, we next transfected PC-3 PCa cells with the HAI-2 plasmid and established stable HAI-2 overexpression transfectants. When compared with control cells, the cells transfected to overexpress HAI-2 exhibited drastically decreased levels of activated matriptase, and concomitantly reduced cell migration and invasion (Figure 4d ). Taken together, these data indicated that HAI-2 likely plays an inhibitory role for the activation of matriptase, and suppresses PCa cell migration and invasion. To dissect the molecular mechanism in which HAI-2 inhibits PCa cell migration and invasion, we investigated whether HAI-2 could inhibit c-Met signaling, as matriptase has been reported to be a protease that can initiate c-Met-induced epithelial carcinogenesis. 44 As shown in Figure 4e (left panels), the tyrosine phosphorylation levels of c-Met in N2 cells were increased approximately twofold as compared with 103E cells, and HAI-2 overexpression in N2 cells dramatically reduced the activity of c-Met, as indicated by tyrosine phosphorylation. Moreover, HAI-2 overexpression also could decrease the phosphorylation levels of Akt (T308) but not the extracellular signal-regulated kinase-1/2 (the two main downstream molecules of c-Met) (Figure 4e , right panel). Taken together, the data indicate that HAI-2 can inhibit matriptase activity, leading to reduction of c-Met signaling, PCa cell migration and invasion.
To further confirm the link between HAI-2 levels and invasive behavior, we made use of a retroviral HAI-2 shRNA construct to suppress HAI-2 expression in CWR22Rv1 cells. HAI-2 protein levels were reduced in shHAI-2-infected CWR22Rv1 cells (Figure 5a , upper-left panel), and the level of activated matriptase was found to be increased in these cells (Figure 5a , lower-left panel), with no significant effect on the cell growth within 2 days (Supplementary Figure 2C) . The suppression of HAI-2 in CWR22Rv1 cells significantly increased the cell migration and invasion (Figure 5a , right panel).
As described above, increased PCa cell migration and invasion caused by HAI-2 knockdown is associated with increased matriptase activation. This suggests the possibility that matriptase HAI-2 in prostate cancer tumorigenicity and metastasis C-H Tsai et al is a target serine protease for inhibition by HAI-2 to modulate PCa cell invasion and migration. To clarify this hypothesis, we analyzed whether the increased cell migration and invasion caused by HAI-2 knockdown could be antagonized by matriptase knockdown. Indeed, the result (Figure 5b) showed that knockdown of matriptase reduced the cell invasion promoted by HAI-2 knockdown, down to the level in control cells. Moreover, recombinant HAI-2 proteins in the conditioned media could also significantly reduce the cell invasion of the shHAI-2 cells (Figure 5c ). Together, these data indicated that matriptase activity in human PCa cells To examine whether multiple HAI-2 bands were caused by glycosylation, N2 cells were transfected with a myc-tagged HAI-2 expression construct and treated with or without tunicamycin (1 mg/ml; Tunica) for 24 h. Cell lysates were harvested and analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted with anti-Myc and anti-HAI-2 Abs. The ' symbol marks endogenous Myc, and the % symbol indicates nonglycosylated HAI-2. (b) Effects of HAI-2 overexpression on matriptase in N2 cells. N2 cells were transfected with vector or HAI-2 expression plasmid, and selected by G418 as stable pools of transfectants. HAI-2 protein levels in HAI-2-overexpressing N2 cells were examined by immunoblotting analysis with an anti-HAI-2 Ab. b-Actin levels were used for loading controls. Cell lysates were also prepared for immunoblotting analysis with anti-total matriptase (M32), anti-HAI-1 (M19) and anti-activated matriptase (M69) under nonboiling and nonreduced conditions. (c) Effect of HAI-2 overexpression on cell invasion and migration of N2 cells. For analyzing the invasion and migration of N2 stable transfectants, cells were seeded at a density of 3 Â 10 5 per chamber and cultured for 16 h. Invasive and migratory cells were conducted as described in Figure 1b . The results were statistically calculated and represented as mean±s.d. of three independent experiments. (d) Effect of HAI-2 overexpression on matriptase, PC3 cell invasion and migration. The effects of HAI-2 overexpression on matriptase, PCa invasion and migration were analyzed in PC3 cells using the same methods as in (b) and (c). *Po0.05. (e) Analysis of phosphorylation levels of c-Met, Akt and extracellular signal-regulated kinase-1/2 (Erk1/2) in 103E/N2 and HAI-2-overexpressing N2/Vec N2 cells using immunoblotting with anti-phospho-c-Met (Y1230/34), anti-c-Met, anti-phospho-Akt (T308), anti-phospho-Akt (S473), Anti-Akt, anti-phospho-ERK1/2 (Thr202/Tyr204 and Thr185/Tyr187 for ERK1 and ERK2, respectively), and anti-ERK Abs. The images were taken by X-ray films and their intensities were measured by a densitometer and statistically calculated with ratios to controls.
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can drive cell invasion and that HAI-2 serves as a potent gatekeeper modulating matriptase activity and the resulting cell migration and invasion.
Matriptase silencing or HAI-2 overexpression inhibits the tumorigenicity and metastasis of prostate cancer To further analyze the roles of matriptase and HAI-2 in the tumorigenicity and metastasis of PCa cells, we injected the stable pools of matriptase-silencing, HAI-2-overexpressing N2 and the respective control cells into the prostate glands of nude mice. As shown in Figure 6a , matriptase silencing or HAI-2 overexpression in N2 cells strikingly reduced the tumor growth in nude mice. This result was confirmed by the primary tumor mass after euthanization (Figure 6b ). Quantification of HAI-1, HAI-2 and matriptase expression using qPCR as well as the protein levels of matriptase and HAI-2 in the tumor tissues showed that matriptase knockdown or HAI-2 overexpression did not significantly affect the expression of the other two genes, and this silencing or overexpression in N2 cells remained stable during the in vivo experiments (Supplementary Figures 3A and B) . Moreover, bioluminescence examination after euthanization revealed (Figure 6c ) that matriptase silencing and HAI-2 overexpression could significantly reduce PCa metastasis to lung tissues in the mice. Hematoxylin and eosin staining (Supplementary Figure 3C) showed that metastatic lesions in lung tissues were significantly decreased in the mice injected with matriptase-silencing and HAI-2-overexpressing N2 cells. These data indicate that HAI-2 exerts an inhibitory effect on invasive tumor growth and metastasis of PCa.
DISCUSSION
Metastasis to distant tissues or organs is a primary cause of human cancer mortality. Cell surface proteolysis has been strongly implicated in cancer cell dissemination and metastasis. In the current study we showed that the expression of HAI-2 was inversely correlated with the progression of PCa cells to a highly invasive and metastatic state. Moreover, the study also showed that in PCa, matriptase was primarily regulated by HAI-2. Reduction in HAI-2 expression resulted in an increase in matriptase activity, PCa cell migration and invasion. Re-establishing high levels of HAI-2 expression or silencing matriptase reduced matriptase activity, tumorigenicity and metastasis of Figure 4c . (c) Effect of recombinant HAI-2 proteins on the HAI-2-knockdown-induced cancer cell invasion. The DNA fragment encoding the extracellular region of HAI-2 was cloned into a secretory vector pSecTag2. HEK293T cells were transfected with the plasmid or vector alone and the stable pools were selected by G418. The stable pools were seeded at a density of 3 Â 10 6 cells in a 6-cm plate within a regular culture medium. The next day, the culture media were refreshed with serum-free RPMI-1640 media. At 24 h after the refreshment, cell lysates (CLs) and the conditioned media (CMs) were collected. The protein concentrations in the CLs were determined by protein assays. Equal amounts of CLs and the CMs from the same cell numbers by normalizing to the whole CLs were used for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot analysis with anti-HAI-2 and anti-His Abs. The CMs were used for the cell invasion assays by adding to the upper and lower chambers. In the lower chambers, 10% fetal bovine serum (FBS) were supplemented as chemoattractant. The cell invasion was analyzed similar to the methods described previously. *Po0.05; ** Po0.01.
PCa. Thus, HAI-2 may serve as an oncosuppressor protein for PCa progression.
To study the metastasis progression of human PCa, we established a metastatic progression model (103E, N1 and N2 cells) by serial orthotopic implantation and isolation of early metastatic cancer cells from nearby lymph nodes. The invasive capability of the cells in this progression series gradually increased throughout the selection. In parallel with the progression to a more invasive and metastatic phenotype, the expression of matriptase by the cells was increased, which mirrors the observation that increased expression of matriptase in human PCa is associated with advanced Gleason scores. 14 We suggest that increased matriptase expression is one factor responsible for enhanced protease activation and increased PCa cell invasion (Figure 3 ). Alternatively, the high level of activated matriptase observed in highly invasive PCa cells might result from the decrease in HAI-2 expression (Figure 5a ). These data demonstrate that both matriptase upregulation and HAI-2 downregulation interact to shift the protease inhibitor balance in a prostate tumor, leading to a more aggressive phenotype. Furthermore, the increased cell invasion resulting from HAI-2 knockdown was significantly blocked by concomitant matriptase knockdown or recombinant HAI-2 proteins in the conditioned medium. This observation suggests that matriptase serves as a key target for HAI-2 in PCa cells, although it has also been proposed that HAI-2 may affect multiple targets in different cell types or developmental stages. 25 In PCa, HAI-2 protein functioned as an inhibitor of cell invasion, tumorigenicity and metastasis, mainly through antagonism of matriptase activity. Moreover, as Figure 6 showed that matriptase silencing or HAI-2 overexpression significantly reduced tumorigenicity, it was possible that the primary effect of the matriptase/HAI-2 axis might be on tumor growth, and these two manipulations to reduce metastasis might be a secondary effect because of smaller primary tumors. In addition, the tumor masses (g) of matriptase-silencing (3.643±0.2822) and HAI-2-overexpressing (2.781 ± 0.3880) N2 orthotopic xenografts were higher than the tumors mass (1.308 ± 0.038) of 103E xenografts following the same procedure. Thus, although these two manipulations can significantly reduce N2 tumor masses, the 'treated' N2 tumors are still bigger than the original 103E tumors. This implies that in addition to the matriptase/HAI-2 axis, there may exhibit some other pathways altered, which also contribute to the progression from 103E to N2 cells.
In addition to matriptase and HAI-2, prostate tissues also express HAI-1, which was the first matriptase inhibitor to be identified. 11 We found that the expression of HAI-1 did not significantly change during the orthotopic growth of PCa cells and in HAI-2-overexpressing and matriptase-silencing N2 xenograft tumors (Supplementary Figure 3) . Thus, these data suggest that the altered expression of HAI-2 and matriptase in PCa cells is independent of HAI-1 expression. This in turn suggests that HAI-2 may play a more important role than HAI-1 in a subset of PCa in modulating protease activation during the metastatic development, although HAI-1 levels have been shown to be inversely correlated with PCa progression. 14 In this study, we also found that HAI-2 overexpression in PCa cells reduced the levels of matriptase/HAI-1 complexes, a surrogate to indicate the activated level of matriptase. 10 One possible reason for the apparent ability of HAI-2 to decrease complex formation between matriptase and HAI-1 might be that high levels of HAI-2 may compete with HAI-1 as an inhibitor for the formation of complexes with activated matriptase, resulting in the loss of matriptase/HAI-1 complexes, as both HAI-1 and HAI-2 have similar in vitro properties as catalytic inhibitors of matriptase. 25 As noncovalent protein complexes may not be observed by immunoblot analysis, it is possible that matriptase/ HAI-2 complexes may not be observed in SDS-polyacrylamide gel electrophoresis in nonreduced and nonboiled conditions in the same way as matriptase/HAI-1 complexes. Thus, the immunoblots showed that HAI-2 overexpression decreased the levels of matriptase/HAI-1 complexes. Alternatively, it is possible that HAI-2 can suppress matriptase activation through some unknown mechanism. Without the proteolytic activation of matriptase, Figure 6 . Analysis of the role of matriptase and HAI-2 in prostate tumor growth and metastasis in xenografted mice. Matriptase (MTX) knockdown (shMTX)/scramble RNA N2 cells and HAI-2-overexpressing/vector-transfected N2 cells were orthotopically xenografted into the anterior prostate of mice (six mice per group). (a) Tumor growth was statistically analyzed employing bioluminescence intensity after the measurement using the IVIS system (Xenogen, PerkinElmer, Taipei, Taiwan) once a week after intraperitoneal (i.p.) injection of D-luciferin at 150 mg/kg. (b) At 6 weeks after implantation, the tumors were excised, imaged and weighed. The average tumor masses from scramble RNA/shMTX N2, vector-transfected and HAI-2-overexpressing N2 xenografted mice were 6.201±0.7007, 3.643±0.2822, 5.879±0.801 and 2.781±0.3880 g (n ¼ 6, mean±s.e.), respectively. Three images per group are presented to represent tumor sizes. The tumor masses in six xenografted mice were calculated and presented as mean ± s.d. *Po0.05; **Po0.01. (c) Analysis of the metastatic lesions in xenografted mice. The metastatic lesions in lung tissues of mice were imaged by the IVIS system (Xenogen) after i.p. injection of D-luciferin at 150 mg/kg (upper panels) and their bioluminescence intensities were statistically plotted and calculated (lower panels).
HAI-1 cannot form a stable complex with matriptase. The detailed mechanism underlying the ability of HAI-2 to reduce matriptase/ HAI-1 complexes is the subject of ongoing investigation.
The decrease in HAI-2 expression during PCa progression may be because of DNA hypermethylation in the HAI-2 promoter, as treatment with 5-Aza-2 0 -deoxycytidine could significantly increase HAI-2 expression in N2 cells (Supplementary Figure 4) . This result is consistent with other reports that the HAI-2 gene is frequently hypermethylated and underexpressed in other malignant cancers. [32] [33] [34] Thus, downregulation of HAI-2 expression often occurs during cancer progression. As some of these studies showed that decreased HAI-2 expression resulted in increased HGF activator (HGFA) activity and HGF maturation, leading to cancer cell invasion in advanced PCa patients, 45 we set out to examine whether HGFA might be a protease target in our PCa cell model; however, we were unable to detect mRNA expression of this protease in these cancer cells. In spite of no detection of HGFA in PCa cells, it is still possible that in vivo circulating HGFA may also be a target for HAI-2 in tumor lesions. In this study, the results from the PCa metastasis progression model and in vivo experiments suggest that matriptase is a key target of HAI-2 that modulates cancer cell invasion, tumor growth and metastasis. One mechanism underlying this modulation is HAI-2-mediated blocking of matriptase for HGF maturation (pro-HGF to HGF), leading to decreases of c-Met activity (Figure 4e ) that might be expected to affect cancer cell invasion (Figure 4c ), tumorigenicity and metastasis ( Figure 6 ). Thus, loss of matriptase inhibition by downregulated HAI-2 can thereby exacerbate PCa by promotion of cancer cell invasion, tumorigenicity and metastasis.
In summary, in this study we established a human PCa progression model through an in vivo selection approach that mimics PCa progression to an advanced stage with enhanced tumorigenicity, cancer cell invasion and metastasis that is, at least in part, because of downregulation of HAI-2 and upregulation of matriptase. The data also support the notion that dysregulation of the HAI-2/matriptase axis in favor of enhanced proteolysis contributes to prostate tumor growth, metastasis and malignancy. Thus, rebalancing the level of cell surface proteolysis either by HAI-2 expression or matriptase inactivation/silencing is tentatively suggested to be a therapeutic strategy for PCa worth pursuing.
MATERIALS AND METHODS
Cell culture
CWR22Rv1, 103E, N1, N2 and PC3 cells were maintained in RPMI-1640 medium with 10% fetal bovine serum (Hyclone, Waltham, MA, USA), 1% glutamine (Sigma-Aldrich, St Louis, MO, USA) and 1% penicillin/streptomycin (Invitrogen, Grand Island, NY, USA).
Orthotopic xenograft of prostate cancer and isolation of the metastatic subline, N1 and N2 Athymic (nu/nu) nude mice (8 weeks old) were obtained from the National Laboratory Animal Center (Taipei, Taiwan) and housed as described previously. 37 The procedure for the establishment of N1 and N2 cells has been described in the Supplementary Materials and methods.
IHC, HAI-2 complementary DNA cloning, western blotting, cell invasion and migration assays and transfection and lentiviral particle preparation Details are provided in the Supplementary Materials and methods.
Statistical analysis
Fisher's exact test was used to evaluate the intensity differences (intensity score^2 vs o2) of IHC signals of matriptase or HAI-2 between tissues with higher and lower Gleason scores. A two-sided P-value of o0.05 was considered statistically significant.
